Clinical trial NCT00919295: Study of Indoleamine 2,3-dioxygenase Activity, Serum Levels of Cytokines, BDNF, BH4 and Mirtazapine Efficacy in Fibromyalgia Syndrome
Official title: Study of Anti-nociceptive Biogenic Amine Status, Indoleamine 2,3-dioxygenase Activity, Serum Levels of Cytokines, BDNF, BH4 and Mirtazapine Efficacy in Thai Fibromyalgia Syndrome Patients.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Fibromyalgia Syndrome
Keywords: Fibromyalgia syndrome
mirtazapine
randomized controlled trial
pilot study
Lead sponsor: Mahidol University
Sponsor class: OTHER
Collaborators: name: University of Texas
name: University of Wuerzburg
First posted: 2009-06-12
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to investigate the anti-nociceptive biogenic amine (serotonin \[5-hydroxytryptamine; 5-HT\], norepinephrine \[NE\], dopamine \[DA\], and their metabolites) status, and serum levels of cytokines, BDNF and BH4 in Thai fibromyalgia syndrome (FMS) patients compared with a representative Thai population. The efficacy and the tolerability of mirtazapine as monotherapy for FMS will also be assessed. In addition, proof of concept of the indoleamine 2,3-dioxygenase (IDO) activity in FMS will be conducted.

The study will be divided into three parts. In part I, FMS patients of Thai ethnicity will be examined to determine the blood and/or urinary level of anti-nociceptive biogenic amines, cytokines, BDNF and BH4 by comparison with the demographically matched, but unrelated, healthy normal controls (HNC). In part II, the FMS subjects from part I study will be randomized to blinded therapy with mirtazapine or identical appearing placebo. There will be three treatment groups (N=1:1:1) to accommodate two dosages of mirtazapine (15 mg, 30mg) and placebo given before bedtime. Pill counts at baseline and at follow-up visits will document compliance. Standard outcome instruments (translated and validated in Thai language) will be used at baseline and at each of the follow-up visits. The co-primary outcome variable will be the changes in the pain visual analog scale (PVAS) score and pain responders (\>= 30% PVAS reduction). Secondary clinical outcome variables of interest will include depression, insomnia, anxiety, physical function, morning stiffness, patient global assessment of disease status, patient global impression of change, fibromyalgia impact questionnaire (FIQ, quality of life and adverse experience. The changes of biogenic amine and IGF-1 concentrations in blood and/or urine with the treatment will be examined as the secondary biochemical measures. In part III, the IDO activity of depressed FMS, non-depressed FMS and HNC will be compared. Moreover, the effect of mirtazapine treatment on the IDO activity in depressed and non-depressed FMS patients will be assessed.

Study hypothesis

1. Anti-nociceptive biogenic amine levels in Thai FMS patients are lower than in Thai healthy normal control.
2. Higher IDO activity could be observed in FMS patients.
3. Higher cytokines could be observed in FMS patients.
4. Higher BDNF could be observed in FMS patients.
5. Lower BH4 could be observed in FMS patients.
6. Mirtazapine is effective in FMS treatment.


Eligibility criteria: Inclusion Criteria for randomized controlled trial:

* male or female outpatients \> 18 years of age, descended from Thai parents
* meet criteria for FMS as defined by the American College of Rheumatology 1990
* have a score of \> 4 on the pain visual analog scale (PVAS) score at screening

Exclusion Criteria:

* any severe or unstable physical or psychiatric disorder
* inflammation or injury or trauma in the previous month
* substance abuse within the past year
* serious suicide risk
* pregnancy or breastfeeding
* subject has an allergic reactions to mirtazapine or any of its constituents or severe allergic reactions to multiple medications
* comorbid inflammatory rheumatic diseases
* Use of medications or herbal agents with CNS activity
* regular use of analgesics with the exception of acetaminophen up to 2 gram/day
* chronic use of sedatives/hypnotics
* unable to discontinue medications that may affect the study results (all antidepressants, mood stabilizers, antipsychotics, sleep aids such as hypnotics, tranquilizers, sedating antihistamine and benzodiazepines, all analgesics including anticonvulsants, muscle relaxants, stimulant medications such as dextroamphetamine and methylphenidate, any other medications taken by the subject for the treatment of fibromyalgia
* unable to attend the follow-up schedule of the study
* not agree with avoidance or stable maintenance of unconventionalor alternative therapies, such as Thai traditional massage

Primary outcomes:
measure: The primary outcome measure for part II of this study will be "change from baseline in the severity of the pain visual analog scale (PVAS) score" and pain responders (>= 30% PVAS reduction).
timeFrame: day 7, 21, 35, 63, 91 (day 0 = first day of starting expected dose)
Secondary outcomes:
measure: Depression, sleep quality, patient global assessment of disease status, FIQ, PGIC, quality of life, adverse events
timeFrame: day 7, 21, 35, 63, 91 (day 0 = the day of starting expected dose)
Other outcomes:
Locations:
city: Bangkoknoi
country: Thailand
facility: Siriraj Hospital, Mahidol University
state: Bangkok
Study officials:
affiliation: Faculty of Pharmacy Mahidol University
name: Suwimon Yeephu
role: PRINCIPAL_INVESTIGATOR
affiliation: Faculty of Pharmacy, Mahidol University
name: Saithip Suttiruksa, Master
role: PRINCIPAL_INVESTIGATOR
References: